2-[4-benzyloxy-3-(3-chloropropoxy)benzylamino]-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-1H-benzimidazole | 858674-30-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[4-benzyloxy-3-(3-chloropropoxy)benzylamino]-1-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-1H-benzimidazole
• 英文别名: [(2R,3R,4R,5R)-3,4-diacetyloxy-5-[2-[[3-(3-chloropropoxy)-4-phenylmethoxyphenyl]methylamino]benzimidazol-1-yl]oxolan-2-yl]methyl acetate
• CAS: 858674-30-3
• 化学式: C₃₅H₃₈ClN₃O₉
• 分子量: 680.154
• InChiKey: GPSGXNXOXXOMQK-YFRBGRBWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  48
• 可旋转键数：
  18
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  136
• 氢给体数：
  1
• 氢受体数：
  11

文献信息

• Benzimidazole derivatives and medical uses thereof
  申请人：Kikuchi Norhiko

  公开号：US20080038242A1

  公开（公告）日：2008-02-14

  The present invention provides benzimidazole derivatives represented by the following formula (I) or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exert an inhibitory activity on sodium-dependent nucleoside transporter 2 and are useful for a disease associated with an abnormality of plasma uric acid level. The compounds of the present invention are useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; R 1 and R 2 are H, a halogen atom, cyano group, optionally substituted alkyl group, optionally substituted aryl group or the like; R 3 is H, a halogen atom, optionally substituted alkyl group or the like; R 4 and R 5 are H, a halogen atom, OH or the like; and R 6 and R X are H or OH: R Y is F or OH.

  本发明提供以下式(I)所表示的苯并咪唑衍生物或其药学上可接受的盐或前药，其对钠依赖性核苷酸转运体2具有抑制活性，并可用于与血浆尿酸水平异常相关的疾病。本发明的化合物可用于痛风、高尿酸血症、尿路结石、高尿酸性肾病等的预防或治疗。在式中，n为1或2；R1和R2为H、卤素原子、氰基、可选取代烷基、可选取代芳基或类似物；R3为H、卤素原子、可选取代烷基或类似物；R4和R5为H、卤素原子、OH或类似物；R6和RX为H或OH；RY为F或OH。
• BENZIMIDAZOLE DERIVATIVES AND MEDICAL USES THEREOF
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1698635B1

  公开（公告）日：2011-12-14
• US7547680B2
  申请人：——

  公开号：US7547680B2

  公开（公告）日：2009-06-16